BioCryst Pharmaceuticals BCRX Increase Decrease In Receivables
Increase Decrease In Receivables at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's increase decrease in receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's increase decrease in receivables?
- BioCryst Pharmaceuticals (BCRX) reported increase decrease in receivables of $474K in Q1 2026.
- How has BioCryst Pharmaceuticals's increase decrease in receivables changed year-over-year?
- BioCryst Pharmaceuticals's increase decrease in receivables decreased by 96.6% year-over-year, from $13.99M to $474K.
- What is the long-term trend for BioCryst Pharmaceuticals's increase decrease in receivables?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's increase decrease in receivables has grown at a 18.3% compound annual growth rate (CAGR), from $22.21M to $36.81M.
- What does increase decrease in receivables mean?
- Measures the net change in amounts owed to the company by customers for goods or services delivered. An increase typically indicates rising sales or potential delays in collections, while a decrease suggests improved cash conversion efficiency.